Genomic newborn and population screening: what osteogenesis imperfecta teaches us about the promise and perils of genomic screening
Disease Models & Mechanisms · 2026-11-01 · 19 (11)
DOI: 10.1242/dmm.053225 ↗Abstract
ABSTRACT Genomic newborn and population screening is rapidly moving from pilot to policy. England's Generation Study has already enrolled tens of thousands of babies, and NHS England has committed to offering whole-genome sequencing to every newborn within a decade. Several such international initiatives, from programmes in Massachusetts and New York to Guangdong, are rapidly expanding gene panels. This expansion, however, is associated with a growing risk of over-calling genomic variants in asymptomatic infants, for whom traditional phenotype-first diagnostic models no longer apply. Osteogenesis imperfecta (OI) provides an instructive test case. It has been long treated as a textbook example of a highly penetrant Mendelian disease; however, population-scale data now show that a substantial proportion of adults carrying ‘pathogenic’ COL1A1/COL1A2 variants have no recorded clinical diagnosis of OI. Using OI as an exemplar, this article explores what genomic screening programmes can realistically deliver, identifies other conditions sharing this penetrance gap, and outlines how programmes can expand without eroding public trust.
EUVIMED